Search Results 71-80 of 21245 for anti-TNF drugs

  1. A Study of the Effectiveness and Safety of Vedolizumab Compared to Adalimumab for Participants with Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) ...

  2. Tocilizumab (Intravenous Route, Subcutaneous Route) Description and Brand Names - Mayo Clinic

    This medicine helps keep joint damage from getting worse after other medicines (eg, adalimumab, etanercept, infliximab) have been used and did not work well. It ...

  3. Drugs - Drug and supplement information - MayoClinic.org

    Look up information about prescription drugs, over-the-counter medications, herbs, vitamins and supplements.

  4. Publications - Sunanda V. Kane, M.D. - Mayo Clinic

    Drugs & Supplements · Healthy Lifestyle · Books ... Effect of Anti-TNF Biologic Exposure During ... Anti-Tumor Necrosis Factor Therapy. Dig Dis Sci ...

  5. Anti-seizure medications: Relief from nerve pain - Mayo Clinic

    Anti-seizure drugs designed to treat epilepsy often are used to control nerve pain associated with diabetes, shingles, and other types of nerve damage.

  6. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    Intolerance, loss response or failure to respond to treatment with at least one TNF-inhibitor within the previous 5 years; Washout of anti-TNF therapy for at ...

  7. Mayo Clinic researchers to present study findings at American College of Gastroenterologists Annual Scientific Meeting

    "When we examined the risk for preeclampsia in those on anti-TNF therapy ... "We theorize that exposure to anti-TNF agents is a marker of more severe ...

  8. Immunosuppressive Drugs Clinical Trials - Mayo Clinic Research

    The purpose of this study is to compare the efficacy of treatment with ustekinumab or adalimumab in biologic naive participants with moderately-to-severely ...

  9. Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 - Mayo Clinic

    ... treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents. Participation eligibility. Participant eligibility includes age, gender, type ...

  10. Breast cancer chemoprevention: Drugs that reduce risk - Mayo Clinic

    Preventive medications can reduce breast cancer risk. Learn about how these drugs work, who should consider taking them, plus their side effects and health ...